Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Shu‐Heng Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8516-6234; OpenAlex author ID A5071426920. Sources: OpenAlex.

Their work

Papers
51 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 6 papers · 2021: 7 papers · 2022: 2 papers · 2023: 6 papers · 2024: 6 papers · 2025: 7 papers · 2026: 5 papers

Papers 50 of 51

  1. Nerve-proximal tertiary lymphoid structures predict chemotherapy sensitivity in pancreatic cancer. Last author DOI 10.1016/j.celrep.2026.117496↗
  2. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.neuron.2026.03.039↗
  3. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03864-z↗
  4. Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.28909↗
  5. L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation Co-author DOI 10.64898/2026.03.06.710237↗
  6. Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenoc… Last author DOI 10.1002/advs.202511726↗
  7. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Co-author DOI 10.1002/cac2.12637↗
  8. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Co-author DOI 10.1002/ctm2.70191↗
  9. Targeting stiff stroma by neutralizing LOX-mediated matrix crosslinking in pancreatic cancer. Last author DOI 10.1016/j.apsb.2025.03.010↗
  10. Peripheral, central, and chemotherapy-induced neuropathic changes in pancreatic cancer. Last author DOI 10.1016/j.tins.2024.11.008↗
  11. ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Co-author DOI 10.1016/j.tranon.2024.102261↗
  12. OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. Co-author DOI 10.7150/thno.103494↗
  13. Retraction Note: Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-024-01383-2↗
  14. Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00852-3↗
  15. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  16. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  17. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  18. Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer. Co-author DOI 10.1186/s12967-024-05363-9↗
  19. Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-023-01020-4↗
  20. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  21. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Co-author DOI 10.1007/s13402-022-00741-1↗
  22. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic … Co-author DOI 10.1007/s13402-023-00824-7↗
  23. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Co-author DOI 10.1007/s13402-023-00829-2↗
  24. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  25. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  26. Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104050↗
  27. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  28. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  29. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  30. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Last author DOI 10.1038/s41419-021-04391-3↗
  31. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  32. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Last author DOI 10.7150/ijbs.49243↗
  33. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  34. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. Co-author DOI 10.1002/jcb.29433↗
  35. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41416-020-0929-0↗
  36. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. Co-author DOI 10.1096/fj.201901237r↗
  37. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  38. Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.7150/thno.38704↗
  39. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Co-author DOI 10.7150/thno.45124↗
  40. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  41. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗
  42. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. First author DOI 10.21037/cco.2019.03.02↗
  43. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗
  44. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2017.10.072↗
  45. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  46. Structural diversity of anti-pancreatic cancer capsimycins identified in mangrove-derived Streptomyces xiamenensis 318 and post-modification via a novel cytoch… First author DOI 10.1038/srep40689↗
  47. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  48. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1038/srep10575↗
  49. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1038/srep15869↗
  50. Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling. First author DOI 10.3892/mmr.2015.3412↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhigang Zhang · 31 shared papers, 2014–2026 · strength 3.70
  2. Li-Peng Hu · 23 shared papers, 2017–2026 · strength 3.24
  3. Yongwei Sun · 23 shared papers, 2015–2024 · strength 2.61
  4. Xiaomei Yang · 15 shared papers, 2015–2026 · strength 2.23
  5. Minwei Yang · 15 shared papers, 2016–2026 · strength 2.15
  6. Xueli Zhang · 12 shared papers, 2019–2026 · strength 1.95
  7. Shan Zhang · 8 shared papers, 2022–2025 · strength 1.71
  8. Yan‐Miao Huo · 13 shared papers, 2015–2026 · strength 1.56
  9. Qing Li · 12 shared papers, 2018–2025 · strength 1.51
  10. Jian‐Yu Yang · 14 shared papers, 2015–2026 · strength 1.45
  11. Luju Jiang · 5 shared papers, 2025–2026 · strength 1.33
  12. Shuqi Cai · 5 shared papers, 2025–2026 · strength 1.33
  13. Hong‐Fei Yao · 7 shared papers, 2022–2026 · strength 1.27
  14. Linli Yao · 7 shared papers, 2021–2026 · strength 1.20
  15. Dejun Liu · 10 shared papers, 2015–2023 · strength 1.13
  16. Qin Yang · 9 shared papers, 2019–2023 · strength 1.04
  17. Xueliang Fu · 7 shared papers, 2016–2026 · strength 0.94
  18. Rong Hua · 10 shared papers, 2015–2023 · strength 0.92
  19. Jia-Hao Zheng · 5 shared papers, 2022–2026 · strength 0.90
  20. Rongkun Li · 8 shared papers, 2014–2023 · strength 0.86
  21. Dong‐Xue Li · 4 shared papers, 2025 · strength 0.84
  22. Xu Wang · 7 shared papers, 2019–2023 · strength 0.83
  23. Lili Zhu · 6 shared papers, 2018–2024 · strength 0.82
  24. Hui Nie · 6 shared papers, 2019–2025 · strength 0.81
  25. Dejun Liu · 5 shared papers, 2016–2026 · strength 0.80

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.